Target Information

Target General Infomation
Target ID
T40010
Former ID
TTDC00238
Target Name
EGF-like domain-containing protein 7
Gene Name
EGFL7
Synonyms
Multiple EGF-like domain protein 7; Multiple epidermal growth factor-like domain protein 7; NOTCH4-like protein; VE-statin; Vascular endothelial statin; ZNEU1; EGFL7
Target Type
Clinical Trial
Disease Non-small-cell lung cancer; Metastatic colorectal cancer [ICD9: 140-199, 140-229, 153, 154, 162, 204.0, 210-229; ICD10: C18-C21, C33, C33-C34, C34, C91.0, D10-D36, D3A]
Function
Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis.
BioChemical Class
Growth factor
Target Validation
T40010
UniProt ID
Q9UHF1
Sequence
MRGSQEVLLMWLLVLAVGGTEHAYRPGRRVCAVRAHGDPVSESFVQRVYQPFLTTCDGHR
ACSTYRTIYRTAYRRSPGLAPARPRYACCPGWKRTSGLPGACGAAICQPPCRNGGSCVQP
GRCRCPAGWRGDTCQSDVDECSARRGGCPQRCVNTAGSYWCQCWEGHSLSADGTLCVPKG
GPPRVAPNPTGVDSAMKEEVQRLQSRVDLLEEKLQLVLAPLHSLASQALEHGLPDPGSLL
VHSFQQLGRIDSLSEQISFLEEQLGSCSCKKDS
Drugs and Mode of Action
Drug(s) MEGF0444A Drug Info Phase 2 Metastatic colorectal cancer; Non-small cell lung cancer [522678]
Anti-EGFL7 Drug Info Phase 1 Non-small-cell lung cancer; Metastatic colorectal cancer [550794]
RG7414 Drug Info Discontinued in Phase 2 Non-small-cell lung cancer; Metastatic colorectal cancer [548970]
Modulator MEGF0444A Drug Info [549982]
RG7414 Drug Info [544335]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
References
Ref 522678ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 548970Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030998)
Ref 550794Clinical pipeline report, company report or official report of Genentech (2011).
Ref 544335Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 2013 September 3; 123(9): 3997-4009.
Ref 549982A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614.
Ref 550794Clinical pipeline report, company report or official report of Genentech (2011).
Ref 550797Clinical pipeline report, company report or official report of Genentech (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.